SCHEMBL4495849 — predicted protein targets

Predicted protein targets (top 19)

	gene	UniProt	supporting neighbours	confidence
▸	GAA	P10253	1/20	0.38

▸	KDM4E	B2RXH2	1/20	0.36

▸	GLA	P06280	1/20	0.36

▸	MAPT	P10636	1/20	0.36

▸	POLB	P06746	1/20	0.34

▸	KMT2A	Q03164	2/20	0.33

▸	PAOX	Q6QHF9	1/20	0.33

▸	LMNA	P02545	1/20	0.33

▸	HTT	P42858	1/20	0.33

▸	TSHR	P16473	1/20	0.33

▸	MEN1	O00255	1/20	0.33

▸	USP2	O75604	1/20	0.32

▸	SMN1; SMN2	Q16637	1/20	0.32

▸	SLC6A2	P23975	1/20	0.32

▸	TP53	P04637	1/20	0.32

▸	PIK3CD	O00329	1/20	0.31

▸	MC4R	P32245	1/20	0.31

▸	HDAC6	Q9UBN7	1/20	0.31

▸	SIGMAR1	Q99720	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL4504097	1.00	GAA (0.38)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4495851	0.78	GAA (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4492236	0.78	GAA (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4504099	0.78	GAA (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4498815	0.77	KDM4E (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4498822	0.77	KDM4E (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL4498818	0.77	KDM4E (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL10273152	0.77	GAA (0.42)	GAAKDM4EGLAMAPTPOLB
SCHEMBL15495015	0.75	GAA (0.41)	GAAKDM4EGLAMAPTPOLB
SCHEMBL14498621	0.75	GAA (0.41)	GAAKDM4EGLAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7501516-B2	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-03-10	—	—	US	claimed
EP-1409481-B1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2006-10-04	—	—	EP	claimed
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2005-01-13	—	—	US	claimed
EP-1409481-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	Astrazeneca AB (SE)	2004-04-21	—	—	EP	claimed
WO-2003008409-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2003-01-30	—	—	WO	claimed
US-7501516-B2	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-03-10	—	—	US	disclosed
EP-1409481-B1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2006-10-04	—	—	EP	disclosed
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2005-01-13	—	—	US	disclosed
EP-1409481-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	Astrazeneca AB (SE)	2004-04-21	—	—	EP	disclosed
WO-2003008409-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2003-01-30	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ABL1, FLT3, JAK2	GAA 1234/4885KDM4E 1156/4885GLA 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.